SEShellie D. Ellis

Shellie D. Ellis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shellie D. Ellis has a total of 241 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Uptake of Risk-Reducing Surgeries in an International Real-World Cohort of Hispanic Women

    by Yanin Chavarri-Guerra, Ana Ferrigno-Guajardo, Cynthia Villarreal-Garza, Bertha Alejandra Martinez-Cannon, Julio Abugattas-Saba, Annette C. Fontaine, Darling J. Horcasitas, Pamela Mora-Alferez, Gary W. Unzeitig, Sandra Brown, et al.

    PURPOSE: Women with pathogenic variants (PVs) in breast cancer (BC) and ovarian cancer (OC) associated genes are candidates for cancer risk-reducing strategies. Limited information is available regarding risk-reducing surgeries (RRS) among Hispanics. The aim of this study was to describe the uptake of RRS in an international real-world experience of Hispanic women referred for genetic cancer risk assessment (GCRA) and to identify factors affecting uptake. METHODS: Between July 1997 and December 2019, Hispanic women, living in the United States or in Latin America, enrolled in the Clinical Cancer Genomics Community Research Network registry were prospectively included. Demographic characteristics and data regarding RRS were obtained from chart reviews and patient-reported follow-up questionnaires. Median follow-up was 41 months. RESULTS: Among 1,736 Hispanic women referred for GCRA, 27.2% women underwent risk-reducing mastectomy (RRM), 25.5% risk-reducing salpingo-oophorectomy (RRSO) and, 10.7% both surgeries. Among BRCA carriers, rates of RRM and RRSO were 47.6% and 56.7%, respectively. In the multivariate analyses, being a carrier of a BC susceptibility gene (odds ratio [OR], 3.44), personal history of BC (OR, 6.22), living in the US (OR, 3.90), age ≤50 years (OR, 1.68) and, family history of BC (OR, 1.56) were associated with a higher likelihood of undergoing RRM. Carrying an OC susceptibility gene (OR, 6.72) was associated with a higher likelihood of undergoing RRSO. CONCLUSION: The rate of RRS among Hispanic women is suboptimal. PV carriers, women with personal history of cancer, and those with a family history of cancer were more likely to have RRS, with less uptake outside the US. Understanding personal and systemic factors influencing uptake may enable interventions to increase risk appropriate uptake of RRS.


  • QIM24-193: Development and Pilot Testing of a Comprehensive Set of Measures for Organizational Assessment of NCCN Guideline Recommended Genomic Testing

    by Shellie Ellis, Aaron Katz, Chao Huang, Samuel Boyd, Carolyn Caine, Whitney Onasch, Daniel Farrell, Jeffrey Thompson, Joaquina Baranda, Rashna Madan, et al.

    "QIM24-193: Development and Pilot Testing of a Comprehensive Set of Measures for Organizational Assessment of NCCN Guideline Recommended Genomic Testing" published on 05 Apr 2024 by National Comprehensive Cancer Network.

  • Open Access

    Determinants of targeted cancer therapy use in community oncology practice: a qualitative study using the Theoretical Domains Framework and Rummler-Brache process mapping

    by Shellie D. Ellis, Joanna Veazey Brooks, Sarah A. Birken, Emily Morrow, Zachary S. Hilbig, Elizabeth Wulff-Burchfield, Anita Y. Kinney, Edward F. Ellerbeck

    Background: Precision medicine holds enormous potential to improve outcomes for cancer patients, offering improved rates of cancer control and quality of life. Not all patients who could benefit from targeted cancer therapy receive it, and some who may not benefit do receive targeted therapy. We sought to comprehensively identify determinants of targeted therapy use among community oncology programs, where most cancer patients receive their care. Methods: Guided by the Theoretical Domains Framework, we conducted semi-structured interviews with 24 community cancer care providers and mapped targeted therapy delivery across 11 cancer care delivery teams using a Rummler-Brache diagram. Transcripts were coded to the framework using template analysis, and inductive coding was used to identify key behaviors. Coding was revised until a consensus was reached. Results: Intention to deliver precision medicine was high across all participants interviewed, who also reported untenable knowledge demands. We identified distinctly different teams, processes, and determinants for (1) genomic test ordering and (2) delivery of targeted therapies. A key determinant of molecular testing was role alignment. The dominant expectation for oncologists to order and interpret genomic tests is at odds with their role as treatment decision-makers’ and pathologists’ typical role to stage tumors. Programs in which pathologists considered genomic test ordering as part of their staging responsibilities reported high and timely testing rates. Determinants of treatment delivery were contingent on resources and ability to offset delivery costs, which low- volume programs could not do. Rural programs faced additional treatment delivery challenges. Conclusions: We identified novel determinants of targeted therapy delivery that potentially could be addressed through role re-alignment. Standardized, pathology-initiated genomic testing may prove fruitful in ensuring patients eligible for targeted therapy are identified, even if the care they need cannot be delivered at small and rural sites which may have distinct challenges in treatment delivery. Incorporating behavior specification and Rummler-Brache process mapping with determinant analysis may extend its usefulness beyond the identification of the need for contextual adaptation.


  • Open Access

    Implementing a home-based virtual hypertension programme—a pilot feasibility study

    by Aditi Gupta, Shellie D Ellis, Crystal Burkhardt, Kate Young, Diego R Mazzotti, Jonathan Mahnken, Noor Abu-El-Rub, Sravani Chandaka, Branden Comfort, Denton Shanks, et al.

    Implementing a health system-based hypertension programme may lower blood pressure (BP). We performed a randomized, controlled pilot study to assess feasibility, acceptability, and safety of a home-based virtual hypertension programme integrating evidence-based strategies to overcome current barriers to BP control. Trained clinical pharmacists staffed the virtual collaborative care clinic (vCCC) to remotely manage hypertension using a BP dashboard and phone “visits” to monitor BP, adherence, side effects of medications, and prescribe anti-hypertensives. Patients with uncontrolled hypertension were identified via electronic health records. Enrolled patients were randomized to either vCCC or usual care for 3 months. We assessed patients’ home BP monitoring behaviour, and patients’, physicians’, and pharmacists’ perspectives on feasibility and acceptability of individual programme components. Thirty-one patients (vCCC = 17, usual care = 14) from six physician clinics completed the pilot study. After 3 months, average BP decreased in the vCCC arm (P = 0.01), but not in the control arm (P = 0.45). The vCCC participants measured BP more (9.9 vs. 1.2 per week, P < 0.001). There were no intervention-related adverse events. Participating physicians (n = 6), pharmacists (n = 5), and patients (n = 31) rated all programme components with average scores of >4.0, a pre-specified benchmark. Nine adaptations in vCCC design and delivery were made based on potential barriers to implementing the programme and suggestions. A home-based virtual hypertension programme using team-based care, technology, and a logical integration of evidence-based strategies is safe, acceptable, and feasible to intended users. These pilot data support studies to assess the effectiveness of this programme at a larger scale.


  • Open Access

    Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey

    by Shellie D. Ellis, Riha Vaidya, Joseph M. Unger, Kelly Stratton, Jessie Gills, Peter Van Veldhuizen, Eileen Mederos, Emily V. Dressler, Matthew F. Hudson, Charles Kamen, et al.


  • Geographic differences in community oncology provider and practice location characteristics in the central United States

    by Shellie D. Ellis, Jeffrey A. Thompson, Samuel S. Boyd, Andrew W. Roberts, Mary Charlton, Joanna Veazey Brooks, Sarah A. Birken, Elizabeth Wulff‐Burchfield, Jonah Amponsah, Shariska Petersen, et al.

    Purpose: How care delivery influences urban‐rural disparities in cancer outcomes is unclear. We sought to understand community oncologists’ practice settings to inform cancer care delivery interventions.Methods: We conducted secondary analysis of a national dataset of providers billing Medicare from June 1, 2019 to May 31, 2020 in 13 states in the central United States. We used Kruskal‐Wallis rank and Fisher's exact tests to compare physician characteristics and practice settings among rural and urban community oncologists.Findings: We identified 1,963 oncologists practicing in 1,492 community locations; 67.5% practiced in exclusively urban locations, 11.3% in exclusively rural locations, and 21.1% in both rural and urban locations. Rural‐only, urban‐only, and urban‐rural spanning oncologists practice in an average of 1.6, 2.4, and 5.1 different locations, respectively. A higher proportion of rural community sites were solo practices (11.7% vs 4.0%, P<.001) or single specialty practices (16.4% vs 9.4%, P<.001); and had less diversity in training environments (86.5% vs 67.8% with P<.001) than urban community sites. Rural multispecialty group sites were less likely to include other cancer specialists.Conclusions: We identified 2 potentially distinct styles of care delivery in rural communities, which may require distinct interventions: (1) innovation‐isolated rural oncologists, who are more likely to be solo providers, provide care at few locations, and practice with doctors with similar training experiences; and (2) urban‐rural spanning oncologists who provide care at a high number of locations and have potential to spread innovation, but may face high complexity and limited opportunity for care standardization.


  • Open Access

    Determinants of Targeted Cancer Therapy Use in Community Oncology Practice: A Qualitative Study using the Theoretical Domains Framework and Rummler-Brache Process Mapping

    by Shellie D Ellis, Joanna Veazey Brooks, Sarah Birken, Emily Morrow, Zachary Hilbig, Elizabeth Wulff-Burchfield, Anita Kinney, Edward Ellerbeck

    BackgroundPrecision medicine holds enormous potential to improve outcomes for cancer patients, offering improved rates of cancer control and quality of life. Not all patients who could benefit from targeted cancer therapy receive it, and some who may not benefit do receive targeted therapy. We sought to comprehensively identify determinants of targeted therapy use among community oncology programs, where most cancer patients receive their care.MethodsGuided by the Theoretical Domains Framework, we conducted semi-structured interviews with 24 community cancer care providers and mapped targeted therapy delivery across 11 cancer care delivery teams using a Rummler-Brache Diagram. Transcripts were coded to the framework using template analysis, and inductive coding was used to identify key behaviors. Coding was revised until consensus was reached.ResultsWe identified distinctly different processes and determinants for 1) somatic and molecular testing and 2) delivery of targeted therapies. Although motivation and intention to offer genomic testing and targeted therapies were high, professional roles and identities were challenged across targeted therapy delivery. Community oncologists’ role as generalist providers was threatened by the knowledge demands of genomic testing. Further oncologists’ role in testing was inconsistent with not only their more traditional role as treatment decision maker, but also pathologists’ role to comprehensively stage tumors. In addition, new roles were emerging or intensifying in the pathology and treatment teams to manage orders from reference laboratories and to ensure patients had access to costly therapies. Professional society guidance and greater institutional standardization were desired for testing, test reporting, and treatment protocols. Benefits for testing (preventing harms and avoiding costs) and treatment (better outcomes, but long-term use without cure) were different and may impact commitment to each behavior differentially.ConclusionsIntervention strategies that address tumor testing and treatment as distinct behaviors with unique determinants may offer promising implementation strategies to improve cancer care delivery as the processes fall to different cancer care delivery teams. Coupling process mapping with determinant analysis may improve the quality of determinant analyses and the subsequent implementation interventions proposed.Trial Registrationn/a

  • Open Access

    Use of implementation science in tobacco control intervention studies in the USA between 2000 and 2020: a scoping review protocol

    by Rebecca Selove, Sarah Neil-Sztramko, Jennifer Leng, Philip J Walker, Ramzi George Salloum, Tamar Ginossar, Carolyn Heckman, Taneisha S Scheuermann, Todd Combs, Raquel Qualls-Hampton, et al.

    Introduction Despite continuing efforts to reduce tobacco use in the USA, decline in smoking rates have stalled and smoking remains a major contributor to preventable death. Implementation science could potentially improve uptake and impact of evidence-based tobacco control interventions; however, no previous studies have systematically examined how implementation science has been used in this field. Our scoping review will describe the use of implementation science in tobacco control in the USA, identify relevant gaps in research and suggest future directions for implementation science application to tobacco control. Methods and analysis Our team, including a medical research librarian, will conduct a scoping review guided primarily by Arksey and O’Malley’s methodology. We will search English language peer-reviewed literature published from 2000 to 31 December 2020 for terms synonymous with ‘tobacco use’, ‘prevention’, ‘cessation’ and ‘implementation science’. The databases included in this search are MEDLINE (PubMed), Embase (Ovid), CINAHL (EBSCOhost), PsycINFO (ProQuest), ERIC (ProQuest) and the Cochrane Library (Wiley). We will include cohort and quasi-experimental studies, single-group experiments and randomised trials that report qualitative and/or quantitative data related to applying implementation science to the planning and/or delivery of interventions to prevent or decrease the use of tobacco products. Studies must target potential or active tobacco users, intervention providers such as educators or healthcare professionals, or US policy-makers. A minimum of two reviewers will independently examine each title and abstract for relevance, and each eligible full text for inclusion and analysis. Use of implementation science, demonstrated by explicit reference to implementation frameworks, strategies or outcomes, will be extracted from included studies and summarised. Ethics and dissemination This study is exempt from ethics board approval. We will document the equity-orientation of included studies with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Equity Extension checklist. Results will be submitted for conferences and peer-reviewed journals. Trial registration number Open Science Framework Registry (6YRK8).


  • Open Access

    Precision community: a mixed methods study to identify determinants of adoption and implementation of targeted cancer therapy in community oncology

    by Jenna Ball, Jeffrey Thompson, Elizabeth Wulff-Burchfield, Edward Ellerbeck, Kim Kimminau, Joanna Veazey Brooks, Shariska Petersen, Duncan Rotich, Anita Y. Kinney, Shellie D. Ellis

    Background: Precision medicine has enormous potential to improve cancer outcomes. Over one third of the 1.5 million Americans diagnosed with cancer each year have genetic mutations that could be targeted with an FDA-approved drug to treat their disease more effectively. However, the current uptake of targeted cancer therapy in clinical practice is suboptimal. Tumor testing is not widely used, and treatments based on molecular and genomic profiling are often not prescribed when indicated. Challenges with the uptake of precision medicine may disproportionately impact cancer patients in rural communities and other underserved populations. The objective of this study is to identify the determinants of adoption and implementation of precision cancer therapy to design an implementation strategy for community oncology practices, including those in rural areas.Methods: This study is an explanatory sequential mixed methods study to identify factors associated with the use of targeted cancer therapy. Levels of targeted therapy use will be ascertained by secondary analysis of medical records to identify concordance with 18 national guideline recommendations for use of precision medicine in the treatment of breast, colorectal, lung, and melanoma skin cancer. Concurrently, facilitators and barriers associated with the use of precision cancer therapy will be elicited from interviews with up to a total of 40 oncologists, administrators, pathology, and pharmacy staff across the participating sites. Qualitative analysis will be a template analysis based on the Theoretical Domains Framework. Quantitative data aggregated at the practice level will be used to rank oncology practices’ adherence to targeted cancer therapy guidelines. Determinants will be compared among high and low users to isolate factors likely to facilitate targeted therapy use. The study will be conducted in eight community oncology practices, with an estimated 4121 targeted therapy treatment decision-making opportunities over a 3-year period.Discussion: Despite unprecedented investment in precision medicine, translation into practice is suboptimal. Our study will identify factors associated with the uptake of precision medicine in community settings. These findings will inform future interventions to increase equitable uptake of evidence-based targeted cancer treatment.